Proximagen to acquire Biovitrum's Cambridge Biotechnology
This article was originally published in Scrip
Executive Summary
Proximagen Neuroscience has signed a letter of intent to acquire Biovitrum's wholly-owned UK-based subsidiary Cambridge Biotechnology (CBT) for a percentage of future revenues generated from CBT's pipeline.